Furthermore, AMP-dNM treatment was demonstrated to reduce the development of atherosclerosis by lowering plasma cholesterol levels in APOE*3-Leiden and low-density lipoprotein receptor -/- mice37. Here, LDLR is linked to atherosclerosis.